SCHEMBL4423289

SCHEMBL4423289

O=[N+]([O-])c1ccc(OP(=O)(O)CNS(=O)(=O)c2ccc(Cl)c(Cl)c2)cc1.[Na]

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 5/20 0.47
CA1 P00915 4/20 0.47
CES2 O00748 1/20 0.47
CES1 P23141 1/20 0.47
LGALS8 O00214 1/20 0.46
LGALS3 P17931 1/20 0.46
VCAM1 P19320 2/20 0.43
MMP2 P08253 3/20 0.41
CA12 O43570 2/20 0.41
CA9 Q16790 2/20 0.41
CA14 Q9ULX7 2/20 0.41
FLT1 P17948 2/20 0.41
FLT4 P35916 2/20 0.41
KDR P35968 2/20 0.41
HSD17B10 Q99714 1/20 0.41
FAAH O00519 2/20 0.41
CYP19A1 P11511 1/20 0.41
KMT2A Q03164 2/20 0.40
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4423288 0.99 CA2 (0.46) CA2CA1CES2CES1LGALS8
SCHEMBL4422643 0.91 VCAM1 (0.55) CA2CA1CES2CES1VCAM1
SCHEMBL4422639 0.90 VCAM1 (0.54) CA2CA1CES2CES1VCAM1
SCHEMBL4420572 0.87 CA2 (0.55) CA2CA1CES2CES1MMP2
SCHEMBL4419753 0.86 FLT1 (0.52) CA2CA1CES2CES1MMP2
SCHEMBL4434415 0.86 NHERF1 (0.47) CA2CA1CES2CES1LGALS8
SCHEMBL4431502 0.85 MEN1 (0.49) CA2CA1CES2CES1MMP2
SCHEMBL4431500 0.84 MEN1 (0.48) CA2CA1CES2CES1MMP2
SCHEMBL4434413 0.84 NHERF1 (0.47) CA2CA1CES2CES1MMP2
SCHEMBL3213558 0.83 ALDH1A1 (0.53) CA2CA1CES2CES1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514556-B2 Inhibitors of β-lactamase METHYLGENE INC. (CA) 2009-04-07 US disclosed
US-20070293675-A1 Novel Inhibitors Of Beta-Lactamase METHYLGENE, INC. (CA) 2007-12-20 US disclosed
US-7259172-B2 phenyl or thien-2-yl substituted amide methyl phosphonate or phosphonyl halide derivatives; do not require a beta -lactam pharmacophore; bactericides; antibiotic resistance METHYLGENE INC. (CA) 2007-08-21 US disclosed
US-20060105999-A1 Novel inhibitors of beta-lactamase METHYLGENE, INC. (CA) 2006-05-18 US disclosed
US-7030103-B2 Sulfonamidomethyl phosphonate inhibitors of β-lactamase METHYLGENE, INC. (CA) 2006-04-18 US disclosed
EP-1194436-B1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF BETA-LACTAMASE METHYLGENE INC (CA) 2005-11-30 EP disclosed
US-6921756-B2 Inhibitors of β-lactamase METHYLGENE, INC. (CA) 2005-07-26 US disclosed
US-6884791-B2 Inhibitors of β-lactamase METHYLGENE, INC. (CA) 2005-04-26 US disclosed
US-20050043276-A1 Novel inhibitors of beta-lactamase METHYLGENE, INC. (CA) 2005-02-24 US disclosed
US-20040082546-A1 Novel Inhibitors of beta-lactamase METHYLGENE, INC. 2004-04-29 US disclosed
US-20040059115-A1 Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase 92229129 QUEBEC INC. (CA) 2004-03-25 US disclosed
US-20040029836-A1 Novel inhibitors of beta-lactamase 92229129 QUEBEC INC. (CA) 2004-02-12 US disclosed
US-6472406-B1 Sulfonamidomethyl phosphonate inhibitors of beta-lactamase METHYLGENE, INC. (CA) 2002-10-29 US disclosed
EP-1194436-A1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF BETA-LACTAMASE Methylgene, Inc. (CA) 2002-04-10 EP disclosed
WO-2001002411-A1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF β-LACTAMASE METHYLGENE INC. (CA) 2001-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043276-A1 Novel inhibitors of beta-lactamase MGAM, LSS, CYP51A1 CA2 2716/4885CA1 4384/4885CES2 174/4885
US-20040029836-A1 Novel inhibitors of beta-lactamase LSS, MGAM, COASY CA2 2629/4885CA1 4178/4885CES2 176/4885
US-20060105999-A1 Novel inhibitors of beta-lactamase LSS, MGAM, LCT CA2 2457/4885CA1 4321/4885CES2 178/4885
US-20040059115-A1 Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase PGLS, MGAM, STS CA2 2859/4885CA1 4176/4885CES2 324/4885
US-20070293675-A1 Novel Inhibitors Of Beta-Lactamase MGAM, LSS, CYP51A1 CA2 2716/4885CA1 4384/4885CES2 174/4885
US-20040082546-A1 Novel Inhibitors of beta-lactamase LSS, MGAM, COASY CA2 2498/4885CA1 4194/4885CES2 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.